Myasthenia Gravis Clinical Trials in Detroit, Michigan

5 studies are recruiting for myasthenia gravis in Detroit, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

   This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects a…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Henry Ford Health Systems, Detroit, Michigan

   Locations

   32 in total

   Run by

   argenx

   See if you can join NCT07284420 on ClinicalTrials.gov

2. ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

   ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Henry Ford Health System, Detroit, Michigan

   Locations

   35 in total

   Run by

   argenx

   See if you can join NCT07294170 on ClinicalTrials.gov

3. Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

   The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Henry Ford Hospital, Detroit, Michigan

   Locations

   17 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07217587 on ClinicalTrials.gov

4. A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

   A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   13 in total

   Run by

   Arcellx, Inc.

   See if you can join NCT06626919 on ClinicalTrials.gov

5. A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

   This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG wh…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Henry Ford Health System, Detroit, Michigan

   Locations

   35 in total

   Run by

   argenx

   See if you can join NCT06298565 on ClinicalTrials.gov